Saturday, July 12, 2025
21.2 C
London
HomeFinTechStarpharma: Continues VIRALEZE success in December quarter

Starpharma: Continues VIRALEZE success in December quarter

Date:

UK Chancellor Reverses ISAs Reductions After Public Backlash

A bold move by the Chancellor to protect savers...

Binance Launches Sharia Earn: An Islamic Banking-Aligned Token

Discover how Binance's new offering caters to Islamic financial...

Ageras Expands Portfolio with 8th Acquisition: Payroll Provider Employes

Strategic Move to Enhance Services in the Accounting and...

Starpharma Continues VIRALEZE success in December quarter

  • Starpharma (SPL) releases its September quarterly report, with the period again highlighted by the continued success of VIRALEZE
  • In late July, VIRALEZE showed a reduction of more than 99.99 per cent against the Delta variant of SARS-CoV-2, the virus that causes COVID-19
  • The VIRALEZE antiviral nasal spray is expected to be launched in Vietnam and Italy next month and SPL is in discussions with other markets in Asia, Europe and India
  • As of September 30, the platform had more than $53.61 million in total available funding, representing 7.6 quarters of use if spending levels remain the same
  • The platform is steady on the market with shares trading at $1.07

Related stories

spot_img

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories